Selective adrenergic uptake inhibitor - Neurocrine

Drug Profile

Selective adrenergic uptake inhibitor - Neurocrine

Alternative Names: Selective norepinephrine reuptake inhibitor - Neurocrine; sNRI - Neurocrine Biosciences

Latest Information Update: 28 Feb 2008

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Class
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Neuropathic pain; Psychiatric disorders; Urinary incontinence

Most Recent Events

  • 05 Feb 2008 Discontinued for Urinary incontinence in USA (unspecified route)
  • 05 Feb 2008 Discontinued - Phase-I for Psychiatric disorders in USA (unspecified route)
  • 05 Feb 2008 Discontinued - Phase-I for Neuropathic pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top